Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers

被引：7
作者：
Coulter, Jonathan B. [1 ]
Easwaran, Hariharan [2 ]
机构：
[1] Johns Hopkins Univ, Brady Urol Inst, Sch Med, Baltimore, MD USA
[2] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Canc Genet & Epigenet, Oncol,Sch Med, Baltimore, MD 21231 USA
来源：
PLOS BIOLOGY | 2023年 / 21卷 / 04期
关键词：
POLYCOMB;
D O I：
10.1371/journal.pbio.3002081
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways. A new study in PLOS Biology demonstrates that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard therapies.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Small molecule inhibitors of EZH2: the emerging translational landscape
    Keilhack, Heike
    Smith, Jesse J.
    EPIGENOMICS, 2015, 7 (03) : 337 - 341
  • [22] Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers
    Cohen, Adam L.
    Piccolo, Stephen R.
    Cheng, Luis
    Soldi, Rafaella
    Han, Bing
    Johnson, W. Evan
    Bild, Andrea H.
    BMC MEDICAL GENOMICS, 2013, 6
  • [23] Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer
    Kong, Yifan
    Zhang, Yanquan
    Mao, Fengyi
    Zhang, Zhuangzhuang
    Li, Zhiguo
    Wang, Ruixin
    Liu, Jinghui
    Liu, Xiaoqi
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (12) : 2490 - 2501
  • [24] Identification of potential inhibitors for EZH2/PRC2 in cancer cells
    Murashima, Akihiro
    Shinjo, Keiko
    Dohi, Natsuki
    Katsushima, Keisuke
    Ito, Akihiro
    Onuki, Tetsuo
    Yoshida, Minoru
    Kondo, Yutaka
    CANCER SCIENCE, 2018, 109 : 621 - 621
  • [25] EZH2 as a novel therapeutic target for atrial fibrosis and atrial fibrillation
    Song, Shuai
    Zhang, Rui
    Mo, Binfeng
    Chen, Long
    Liu, Liang
    Yu, Yi
    Cao, Wei
    Fang, Guojian
    Wan, Yi
    Gu, Yue
    Wang, Yuepeng
    Li, Yigang
    Yu, Ying
    Wang, Qunshan
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2019, 135 : 119 - 133
  • [26] Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells
    Jin, Mengyuan
    Duan, Jiachen
    Liu, Wei
    Ji, Jing
    Liu, Bin
    Zhang, Mingzhi
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [27] Dual-target EZH2 inhibitor: latest advances in medicinal chemistry
    Wei, Lai
    Mei, Dan
    Hu, Sijia
    Du, Shufang
    FUTURE MEDICINAL CHEMISTRY, 2024, 16 (15) : 1561 - 1582
  • [28] Prognostic significance of EZH2 expression in patients with digestive cancers: a meta-analysis
    Wang, Wei
    Wang, Feng
    Zong, Guangquan
    Liu, Renmin
    Zhang, Yufei
    Luan, Yang
    Xu, Lin
    Xuan, Ji
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (09): : 16043 - 16049
  • [29] USP7 deubiquitinates and stabilizes EZH2 in prostate cancer cells
    Lee, Jae Eun
    Park, Chan Mi
    Kim, Jung Hwa
    GENETICS AND MOLECULAR BIOLOGY, 2020, 43 (02) : 1 - 12
  • [30] A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors
    Liang, Rui
    Tomita, Daisuke
    Sasaki, Yusuke
    Ginn, John
    Michino, Mayako
    Huggins, David J.
    Baxt, Leigh
    Kargman, Stacia
    Shahid, Maaz
    Aso, Kazuyoshi
    Duggan, Mark
    Stamford, Andrew W.
    DeStanchina, Elisa
    Liverton, Nigel
    Meinke, Peter T.
    Foley, Michael A.
    Phillips, Richard E.
    ACS MEDICINAL CHEMISTRY LETTERS, 2022, 13 (03): : 377 - 387
12345